News
San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug.
Investing.com -- Hims & Hers CEO Andrew Dudum has shared new information about the company’s terminated partnership with Novo Nordisk (NYSE: NVO ), which ended in June 2025, in an interview with The ...
We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Hims & Hers Health, Inc.
The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in. | Novo ...
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...
Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...
Ozempic, which is prescribed for diabetes, and Wegovy, prescribed for weight loss, both contain the active ingredient ...
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
Hims & Hers Health (NYSE: HIMS) is a telehealth company that offers personalized solutions for its customers. While ...
StockStory.org on MSN5d
Hims & Hers Health (HIMS) Stock Is Up, What You Need To KnowShares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.1% in the morning session after the company announced ...
Hims & Hers' high valuation is no longer justified amid mounting execution and revenue risks. Click here to read why I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results